申请人:Evans M. David
公开号:US20050043299A1
公开(公告)日:2005-02-24
Novel compounds that are inhibitors of one or most post-proline cleaving proteases, e.g. dipeptidyl peptidase IV, according to general formula (1). R
1
is H or CN, X
1
is O, S, CH
2
, CHF, CF
2
, CH(CH
3
), C(CH
3
)
2
or CH(CN), and b is 1 or 2. G
1
is H or a group according to the formula —CH
2
—X
2
—(CH
2
)
a
—G
3
and G
2
is H or a group according to the formula —CH
2
—(CH
2
9
a
—G
3
, provided that one of G
1
and G
2
is H and the other is not H. X
2
is O, S, or CH
2
, and a is 0, 1 or 2, provided that when a is 1 then X
2
is CH
2
. G
3
is a group according to one of general formulae 2-4, where the variables have meaning given in the description. The compounds are useful in the treatment of i.a. type 2 diabetes and impaired glucose tolerance.
一种新型化合物,根据通式(1),其为一种或多种后脯氨酸裂解蛋白酶的抑制剂,例如二肽基肽酶IV。其中,R1为H或CN,X1为O、S、CH2、CHF、CF2、CH(CH3)、C(CH3)2或CH(CN),b为1或2;G1为H或按照公式—CH2—X2—(CH2)a—G3的基团,G2为H或按照公式—CH2—(CH2)9a—G3的基团,其中G1和G2中的一个为H,另一个不为H;X2为O、S或CH2,a为0、1或2,当a为1时,X2为CH2;G3为根据公式2-4中的任意一种的基团,其中变量的含义在说明中给出。这些化合物在治疗2型糖尿病和糖耐量受损等方面有用。